Daniel C Rose

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT”.

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004218

N/A

0.965DataRank · unranked

31 citations

Daniel C Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, William L. Redmond +1 more

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000464

N/A

0DataRank · unranked

31 citations

Annah S. Rolig, Deborah H. Charych, Ute Hoch, Melissa J. Kasiewicz, Daniel C Rose +4 more